Browse Studies — Arctuva

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

Estimated

~$10 – $7,500

Institut de Recherches Internationales ServierNCT05786924

Phase 1

A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib or Encorafenib/Binimetinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition

This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresecta…

Metastatic MelanomaBRAF Gene Mutation

Estimated

~$10 – $7,500

Rina PlattnerNCT04903119

Phase 1

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of…

OncologyMEK MutationRAF Gene Mutation+6 more

Estimated

~$10 – $8,750

Nested Therapeutics, IncNCT06326411